Suppr超能文献

规范基于急诊科的偏头痛研究:常用临床试验结局测量指标的分析。

Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures.

机构信息

Department of Emergency Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

出版信息

Acad Emerg Med. 2010 Jan;17(1):72-9. doi: 10.1111/j.1553-2712.2009.00587.x.

Abstract

OBJECTIVES

Although many high-quality migraine clinical trials have been performed in the emergency department (ED) setting, almost as many different primary outcome measures have been used, making data aggregation and meta-analysis difficult. The authors assessed commonly used migraine trial outcomes in two ways. First, the authors examined the association of each commonly used outcome versus the following patient-centered variable: the research subject's wish, when asked 24 hours after investigational medication administration, to receive the same medication the next time they presented to an ED with migraine ("would take again"). This variable was chosen as the criterion standard because it provides a simple, dichotomous, clinically sensible outcome, which allows migraineurs to factor important intangibles of efficacy and adverse effects of treatment into an overall assessment of care. The second part of the analysis assessed how sensitive to true efficacy each outcome measure was by calculating sample size requirements based on results observed in previously conducted clinical trials.

METHODS

This was a secondary analysis of data previously collected in four ED-based migraine randomized trials performed between 2003 and 2007. In each of these trials, subjects were asked 24 hours after administration of an investigational medication whether or not they would want to receive the same medication the next time they came to the ED with a migraine. Odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for sex and medication received, were calculated as measures of association between the most commonly used outcome measures and "would take again." The sensitivity of each outcome measure to treatment efficacy was determined by calculating the sample size that would be required to detect a statistically significant result using estimates of that outcome obtained in two clinical trials.

RESULTS

Data from 378 subjects were used for this analysis. Adjusted ORs for association of "would take again" and other commonly used primary headache outcomes are as follows: achieving a pain-free state by 2 hours, OR = 3.1 (95% CI = 1.8 to 5.4); sustained pain-free status, OR = 4.5 (95% CI = 1.9 to 11.0); and no need for rescue medication, OR = 3.7 (95% CI = 2.1 to 6.6). An improvement on a standardized 11-point pain scale of > or =33% had an adjusted OR = 5.2 (95% CI = 2.2 to 12.4). The best performing alternate outcome, > or =33% improvement, correctly classified 288 subjects and misclassified 77 subjects when compared to "would take again." At least 33% improvement and pain-free by 2 hours required the smallest sample sizes, while sustained pain-free and "would take again" required many more subjects.

CONCLUSIONS

"Would take again" was associated with all migraine outcome measures we examined. No individual outcome was more closely associated with "would take again" than any other. Even the best-performing alternate outcome misclassified more than 20% of subjects. However, sample sizes based on "would take again" tended to be larger than other outcome measures. On the basis of these findings and this outcome measure's inherent patient-centered focus, "would take again," included as a secondary outcome in all ED migraine trials, is proposed.

摘要

目的

虽然在急诊室(ED)环境中进行了许多高质量的偏头痛临床试验,但使用了几乎同样多的不同主要结局指标,使得数据汇总和荟萃分析变得困难。作者以两种方式评估了常用的偏头痛试验结局。首先,作者检查了每个常用结局与以下以患者为中心的变量的关联:在接受研究药物治疗后 24 小时,研究对象是否希望在下一次因偏头痛就诊 ED 时接受相同的药物(“愿意再次服用”)。选择这个变量作为标准,因为它提供了一个简单、二分、临床上合理的结局,可以让偏头痛患者将治疗效果和不良反应的重要无形因素纳入整体护理评估。分析的第二部分通过计算基于先前进行的临床试验中观察到的结果的样本量要求来评估每个结局指标对真实疗效的敏感性。

方法

这是对 2003 年至 2007 年间进行的四项基于 ED 的偏头痛随机试验中收集的数据进行的二次分析。在这些试验中的每一项中,在给予研究药物后 24 小时,询问受试者是否愿意在下一次因偏头痛就诊 ED 时接受相同的药物。计算调整了性别和接受药物的比值比(OR)及其 95%置信区间(CI),作为最常用结局指标与“愿意再次服用”之间关联的衡量标准。使用从两项临床试验中获得的该结局估计值,计算每种结局指标对治疗效果的敏感性,得出需要的样本量,以检测到具有统计学意义的结果。

结果

对 378 名受试者的数据进行了此项分析。“愿意再次服用”和其他常用原发性头痛结局的关联的调整后 OR 如下:2 小时内达到无痛状态,OR = 3.1(95%CI = 1.8 至 5.4);持续无痛状态,OR = 4.5(95%CI = 1.9 至 11.0);无需使用解救药物,OR = 3.7(95%CI = 2.1 至 6.6)。标准化 11 分疼痛量表的改善≥33%,调整后 OR = 5.2(95%CI = 2.2 至 12.4)。表现最好的替代结局,改善≥33%,与“愿意再次服用”相比,正确分类了 288 名受试者,错误分类了 77 名受试者。≥33%的改善和 2 小时内无痛需要的样本量最小,而持续无痛和“愿意再次服用”则需要更多的受试者。

结论

“愿意再次服用”与我们检查的所有偏头痛结局指标都相关。没有任何一个结局指标比其他结局指标更密切地与“愿意再次服用”相关。即使是表现最好的替代结局,也错误分类了超过 20%的受试者。然而,基于“愿意再次服用”的样本量往往大于其他结局指标。基于这些发现和该结局指标固有的以患者为中心的重点,我们提出将“愿意再次服用”作为所有 ED 偏头痛试验的次要结局纳入其中。

相似文献

引用本文的文献

本文引用的文献

6
The International Classification of Headache Disorders: 2nd edition.《国际头痛疾病分类:第二版》
Cephalalgia. 2004;24 Suppl 1:9-160. doi: 10.1111/j.1468-2982.2003.00824.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验